Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have announced that aflibercept (injection 8 mg) met the primary endpoint for the treatment of patients with macular oedema following… Read More »Aflibercept injection (8 mg, Eylea HD) for the treatment of macular oedema following retinal vein occlusion (RVO) meets primary endpoint.
Dear EURETINA Members, A very warm welcome to the December 21st, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »December 21st, 2024 “EURETINA-Brief”© Issue No. 306
Researchers at the Gavin Herbert Eye Institute, Department of Ophthalmology, University of California, Irvine, has reported an experimental treatment using a CRISPR/Cas9 adenine base editing… Read More »Autosomal-recessive retinitis pigmentosa (arRP) – a mutation (E150K) of rhodopsin may provide a CRISPR treatment with functional and structural rescue.
Researchers at the Casey Eye Institute, Oregon Health & Science University (OHSU), Portland, USA, have provided formal results of a Phase 1/2 study, published at… Read More »A phase 1/2 multi-centre study provides results for the treatment of XLRP, promising a Phase 2/3 study to progress in 2025.
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company based in Iselin, New Jersey, USA, has announced that the UK NICE (National Institute for Health and… Read More »Outlook Therapeutics (NASDAQ: OTLK) announce first and only approved ophthalmic formulation of bevacizumab (for treatment of wet AMD) in the EU and UK.
Kanski’s Clinical Ophthalmology – A Systematic Approach, 10th edition, by John F. Salmon (Elsevier) The 10th edition of Kanski’s Clinical Ophthalmology is a comprehensive… Read More »Kanski’s Clinical Ophthalmology – A Systematic Approach, 10th edition, by John F. Salmon (Elsevier)
Dear EURETINA Members, A very warm welcome to the December 5th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »December 5th, 2024 “EURETINA-Brief”© Issue No. 305
A team of Korean researchers have published a study using an AI-model of optical coherence tomography (OCT) image data to predict AMD treatment outcomes following… Read More »Korean research team provide an Artificial intelligence (AI) tool for predicting the treatment response of nAMD based on OCT biomarkers.
Researchers at the Department of Ophthalmology, Ajou University School of Medicine, Suwon, Republic of Korea, have outlined an increasing future burden of depressive disorders, providing… Read More »An investigation of the association between Retinitis pigmentosa (RP) and depressive disorder, including a call for practical training and methods.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the marketing authorization of… Read More »The CHMP (EMA) has issued a positive opinion for the marketing authorisation of FYB203, a biosimilar candidate to Eylea (Aflibercept).
